Given the central role of HIF-1 in the pathophysiology of glioblastoma, the identification of a specific HIF-1 inhibitor holds promise for overcoming resistance to cytotoxic therapy and improving overall survival. The gene discussed is HIF1A; the disease is glioblastoma.